| 23047 |
Dupilumab |
Dupixent® |
Dupilumab (Dupixent®) is indicated for the treatment of adults and adolescents 12 years and older, weighing at least 40 kg, with eosinophilic oesophagitis (EoE) who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy. |
Rapid Review Complete |
7th September 2023 |
 |
| 19056 |
Dupilumab |
Dupixent® |
For the treatment of moderate-to-severe atopic dermatitis in adolescents 12 years and older who are candidates for systemic therapy. |
Rapid review complete |
17th January 2020 |
|
| 23043 |
Dupilumab |
Dupixent® |
Dupilumab (Dupixent®) is indicated for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. |
Rapid Review Complete |
24th August 2023 |
|
| 23044 |
Dupilumab |
Dupixent® |
Dupilumab (Dupixent®) is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment. |
Rapid Review Complete |
5th September 2023 |
|
| 21063 |
Dupilumab |
Dupixent® |
For adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance. |
Rapid review complete |
8th February 2022 |
|
| 21035 |
Dupilumab |
Dupixent® |
For severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy. |
Rapid review complete |
23rd September 2021 |
|
| 23042 |
Dupilumab |
Dupixent® |
Dupilumab is indicated for the treatment of severe atopic dermatitis in children aged 6 months to 6 years old who are candidates for systemic therapy. |
Rapid Review Complete |
1st September 2023 |
|
| 23046 |
Dupilumab |
Dupixent® |
Dupilumab (Dupixent®) is indicated as an add-on therapy with intranasal corticosteroids, for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. |
Rapid Review Complete |
5th September 2023 |
|
| - |
Dupilumab |
Dupixent® |
For treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. |
NCPE Assessment Process Complete |
12th December 2019 |
|
| - |
Durvalumab |
Imfinzi® |
For the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 ≥1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT). |
NCPE Assessment Process Complete |
7th May 2020 |
|
| 21033 |
Durvalumab |
Imfinzi® |
In combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer. |
Rapid review complete |
9th September 2021 |
|
| 23009 |
Durvalumab |
Imfinzi® |
Durvalumab in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adults with unresectable or metastatic biliary tract cancer. |
Awaiting full HTA submission from Applicant |
6th June 2023 |
|
